Boehringer exercises option for Eureka's TCR-mimicking antibodies

Boehringer Ingelheim GmbH (Ingelheim, Germany) exercised a 2015 option to exclusively license human TCR-mimicking antibodies against an undisclosed cancer target from Eureka Therapeutics Inc. (Emeryville, Calif.). Eureka will receive an undisclosed option payment and is eligible for development and sales milestones, as well as royalties (see "Boehringer Ingelheim, Eureka Therapeutics Deal").

The antibodies are based on Eureka’s E-ALPHA discovery platform, which is designed to generate antibodies that can target extracellular and intracellular antigens...